Were Noah Goodman’s Kymera (KYMR) share sales part of a Rule 10b5-1 trading plan?

Yes. Footnotes state the transactions were executed under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans pre-schedule trades, making the timing more routine and less indicative of short-term views on the stock.

Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options and sold shares in a planned series of transactions. On April 9, he exercised options to acquire 2,500 shares of common stock at an exercise price of $21.05 per share and continued to hold 97,500 options afterward. He then sold a total of 10,264 shares of common stock on April 9 and 10 in open-market transactions at weighted average prices around the mid-$80s to high-$80s. Footnotes state that some shares were sold automatically to cover tax withholding on vested RSUs and that the trades were made under a Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly holds 51,542.438 shares of Kymera common stock.

Insights

Routine option exercise plus pre-planned, partly tax-driven sales; insider retains a sizable equity stake.

Chief Business Officer Noah Goodman exercised stock options for 2,500 shares of Kymera Therapeutics common stock at an exercise price of $21.05 per share, while 97,500 options remain outstanding. This converts a portion of his derivative compensation into outright share ownership.

He then sold 10,264 shares in open-market trades at weighted average prices in the mid-$80s to high-$80s, with sales on April 9–10, 2026. Footnotes explain that some shares were automatically sold to cover tax withholding on RSU vesting and that all transactions occurred under a Rule 10b5-1 trading plan dated December 10, 2025, indicating pre-planned, largely mechanical activity.

After these trades, Goodman still holds 51,542.438 shares directly, alongside 97,500 remaining options. The scale relative to his continuing holdings and the pre-arranged 10b5-1 plan framework suggest these are routine liquidity and tax-management moves rather than a directional call on Kymera’s prospects.

Insider Trade Summary 10b5-1

Net Seller: 10,264 shares ($897,782)

Net Sell 6 txns

Insider Goodman Noah

Role Chief Business Officer

Sold 10,264 shs ($898K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$87.35	$175K
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$21.05	$53K
Sale	Common Stock	3,094	$86.618	$268K
Sale	Common Stock	2,670	$87.1109	$233K
Sale	Common Stock	2,500	$89.00	$223K

Holdings After Transaction: Common Stock — 51,542.438 shares (Direct); Stock Option (Right to Buy) — 97,500 shares (Direct)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.005 to $86.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.015 to $87.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

Key Figures

Options exercised: 2,500 shares Option exercise price: $21.05 per share Shares sold: 10,264 shares +4 more

7 metrics

Options exercised 2,500 shares Stock option exercise into common stock on April 9, 2026

Option exercise price $21.05 per share Exercise price for 2,500 stock options

Shares sold 10,264 shares Open-market sales on April 9–10, 2026

Sale price example $87.35 per share Open-market sale price on April 10, 2026

Post-trade holdings 51,542.438 shares Common stock directly held after reported transactions

Remaining stock options 97,500 options Options outstanding after the April 9, 2026 exercise

Higher sale price example $89.00 per share One reported weighted average sale price on April 9, 2026

Key Terms

Rule 10b5-1 trading plan, RSUs, Stock Option (Right to Buy), weighted average price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSUs financial

"sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with an exercise price of 21.0500"

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting financial

"shares required to be sold ... in connection with the vesting of RSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/10/2026 - 04:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodman Noah

(Last)

(First)

(Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/09/2026		M⁽¹⁾		2,500	A	$21.05	61,806.438	D
Common Stock	04/09/2026		S⁽²⁾		3,094	D	$86.618⁽³⁾	58,712.438	D
Common Stock	04/09/2026		S⁽²⁾		2,670	D	$87.1109⁽⁴⁾	56,042.438	D
Common Stock	04/09/2026		S⁽¹⁾		2,500	D	$89	53,542.438	D
Common Stock	04/10/2026		S⁽¹⁾		2,000	D	$87.35	51,542.438	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$21.05	04/09/2026		M⁽¹⁾			2,500	⁽⁵⁾	04/07/2035	Common Stock	2,500	$0	97,500	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.005 to $86.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.015 to $87.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Kymera Therapeutics (KYMR) executive Noah Goodman do in this Form 4 filing?

Noah Goodman exercised options and sold Kymera shares. He acquired 2,500 shares at an exercise price of $21.05, then sold 10,264 shares in open-market transactions, while remaining a substantial shareholder after the trades.

How many Kymera Therapeutics (KYMR) shares did Noah Goodman sell and at what prices?

Noah Goodman sold 10,264 Kymera common shares. The reported weighted average sale prices ranged from about $86 to $89 per share across multiple open-market trades executed on April 9 and April 10, 2026.

How many Kymera (KYMR) shares and options does Noah Goodman hold after these transactions?

After the transactions, Noah Goodman directly holds 51,542.438 Kymera common shares. He also retains 97,500 stock options, reflecting a continued, significant equity-linked exposure to the company’s performance going forward.

Why were some of Noah Goodman’s Kymera (KYMR) shares sold automatically?

A footnote explains that certain shares were sold to cover tax withholding obligations tied to vesting restricted stock units (RSUs). These tax-related sales were automatic and not made at Noah Goodman’s discretion, reflecting standard equity compensation mechanics.

What is the significance of the option exercise reported for Kymera (KYMR) in this Form 4?

The filing shows Goodman exercised stock options for 2,500 Kymera shares at $21.05 per share. This converts part of his option grant into common stock, while he still holds 97,500 options that continue to link his pay to Kymera’s future share performance.